Sébastien Fortin is a Full Professor at the Faculty of Pharmacy, Laval University, and a researcher at the Research Center of the CHU of Quebec – Laval University, where he leads the Oncology Axis. He is actively engaged in both teaching and research, with a strong focus on targeted cancer therapies and pharmaceutical chemistry. Bachelor's degree in Chemistry, Laval University Master's degree in Pharmacy, Laval University Joint Doctorate in Pharmacy (Laval University) and Life and Health Sciences (Auvergne 1 University, France) Postdoctoral Internship in Pharmacy, Laval University Postdoctoral Internship in Chemistry-Biology, University of Quebec in Trois-Rivières His research interests lie at the intersection of fundamental and translational science, particularly in the development of innovative anticancer agents. His work emphasizes targeted therapies , with projects focusing on prodrug development for breast cancer , characterization of amino acid transporters , and novel agents for acute myeloid leukemia (AML) . He employs a multidisciplinary approach combining pharmaceutical chemistry, molecular and cellular biology, pharmacology, and molecular modeling. The recent publications highlight a consistent trajectory in CYP1A1-targeted prodrugs , antimitotic agents , and metabolic inhibitors like DHODH . His team has developed novel families of compounds such as N-alkylphenylimidazolidones (AIMZs) and phenyl ureidobenzenesulfonates (PUB-SOs), demonstrating selective cytotoxicity and differentiation-inducing properties in cancer cells. These studies span from chemical synthesis to in vitro and in vivo evaluation, reflecting a robust drug discovery pipeline. Bourse de carrière (niveau junior 2), FRQS (2023–2026) Bourse de carrière (niveau junior 1), FRQS (2018–2022) Prix de la meilleure thèse en cotutelle franco-québécoise (2011) Prix de recherche GlaxoSmithKline/AFPC (2012) IRSC Postdoctoral Fellowship (2012) FRQS Doctoral Fellowship (2007–2009) Dr. Fortin supervises several graduate students and has secured significant funding from national agencies including NSERC, CIHR, and Fonds de recherche du Québec. His research is supported by infrastructure grants from the Canada Foundation for Innovation (CFI). He collaborates with professionals and students in his research team, advancing projects from molecular design to preclinical validation. His lab is involved in cutting-edge work on molecular probes for amino acid transporters , precision oncology , and drug delivery systems , positioning his research at the forefront of modern pharmaceutical sciences.






